Key Points
-
Although the results of treatment with conventional chemotherapy and surgery for advanced ovarian cancer have gradually improved, the majority of women still die with drug-resistant disease after 5 years. Our improved understanding of the underlying biology of ovarian cancer is now leading to the development of molecular targeted therapies, which aim to address this major clinical need.
-
Anti-angiogenic cancer therapies such as bevacizumab have shown efficacy in early-phase ovarian cancer clinical trials and are likely to become part of standard therapy for advanced ovarian cancer in the future.
-
A poly (ADP-ribose) polymerase inhibitor has shown substantial anti-tumour activity as a single-agent therapy in germline BRCA-deficient patients with ovarian cancer in early clinical trials; further studies assessing its role in sporadic ovarian cancers are now underway.
-
Genetic and epigenetic aberrations that drive ovarian cancer have been discovered. These drive key oncogenic signalling pathways, such as the PI3K–Akt pathway, and might be potential targets for anticancer therapeutics, either as monotherapy or in combination with established cytotoxic chemotherapies.
-
Pharmacodynamic biomarkers, which provide proof-of-principle of target modulation and predictive biomarkers, which could be used for patient selection, are essential in the development of novel molecular targeted therapies for ovarian cancer.
-
It is expected that the development of novel anticancer therapies, particularly as maintenance treatments, might lead to the prolonged survival of patients with ovarian tumours in the future.
Abstract
Ovarian cancer is the leading cause of death from gynaecological malignancies in the Western world. Despite the evolution of surgical techniques and meticulously designed chemotherapy regimens, relapse remains almost inevitable in patients with advanced disease. In an age when great advances have been made in understanding the genetics and molecular biology of this heterogeneous disease, it is likely that the introduction of novel targeted therapies will have a major impact on the management of ovarian cancer. Importantly, such strategies might allow selection of treatments based on the molecular characteristics of tumours and bring us closer to an era of personalized medicine.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Parkin, D. M., Bray, F., Ferlay, J. & Pisani, P. Global cancer statistics, 2002. CA Cancer J. Clin. 55, 74–108 (2005).
Jemal, A. et al. Cancer statistics, 2008. CA Cancer J. Clin. 58, 71–96 (2008).
Dinh, P., Harnett, P., Piccart-Gebhart, M. J. & Awada, A. New therapies for ovarian cancer: cytotoxics and molecularly targeted agents. Crit. Rev. Oncol. Hematol. 67, 103–112 (2008).
Agarwal, R. & Kaye, S. B. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nature Rev. Cancer 3, 502–516 (2003).
Balvert-Locht, H. R. et al. Improved prognosis of ovarian cancer in the Netherlands during the period 1975–1985: a registry-based study. Gynecol. Oncol. 42, 3–8 (1991).
Mutch, D. G. Surgical management of ovarian cancer. Semin. Oncol. 29, 3–8 (2002).
Ozols, R. F. et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J. Clin. Oncol. 21, 3194–3200 (2003). A key study that confirmed the role of paclitaxel and carboplatin in ovarian cancer treatment.
du Bois, A., Neijt, J. P. & Thigpen, J. T. First line chemotherapy with carboplatin plus paclitaxel in advanced ovarian cancer — a new standard of care? Ann. Oncol. 10 (Suppl. 1), 35–41 (1999).
Biagi, J. J. & Eisenhauer, E. A. Systemic treatment policies in ovarian cancer: the next 10 years. Int. J. Gynecol. Cancer 13 (Suppl. 2), 231–240 (2003).
Neijt, J. P. et al. Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J. Clin. Oncol. 18, 3084–3092 (2000).
Sandercock, J., Parmar, M. K., Torri, V. & Qian, W. First-line treatment for advanced ovarian cancer: paclitaxel, platinum and the evidence. Br. J. Cancer 87, 815–824 (2002). An important editorial that raises questions about the extent of benefit of paclitaxel and carboplatin over single-agent carboplatin.
Greenlee, R. T., Hill-Harmon, M. B., Murray, T. & Thun, M. Cancer statistics, 2001. CA Cancer J. Clin. 51, 15–36 (2001).
Gore, M. E., Fryatt, I., Wiltshaw, E. & Dawson, T. Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol. Oncol. 36, 207–211 (1990). One of the first papers to describe the importance of the platinum-free interval following platinum-based treatment in ovarian cancer.
De Placido, S. et al. Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study. J. Clin. Oncol. 22, 2635–2642 (2004).
Bookman, M. A., Greer, B. E. & Ozols, R. F. Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel vs. cisplatin and paclitaxel (GOG 158) and an update on GOG0 182-ICON5. Int. J. Gynecol. Cancer 13, 735–740 (2003).
Monk, B. J. et al. A randomized phase III study of trabectedin with pegylated liposomal doxorubiciin (PLD) versus PLD in relapsed, recurrent ovarian cancer (OC). Ann. Oncol., 19, (Supp. 8), viii1–viii4 (2008).
Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57–70 (2000). A key paper that describes the major therapeutic targets in cancer.
Hicklin, D. J. & Ellis, L. M. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J. Clin. Oncol. 23, 1011–1027 (2005).
Martin, L. & Schilder, R. Novel approaches in advancing the treatment of epithelial ovarian cancer: the role of angiogenesis inhibition. J. Clin. Oncol. 25, 2894–2901 (2007).
Ramakrishnan, S., Subramanian, I. V., Yokoyama, Y. & Geller, M. Angiogenesis in normal and neoplastic ovaries. Angiogenesis 8, 169–182 (2005).
Burger, R. A. Experience with bevacizumab in the management of epithelial ovarian cancer. J. Clin. Oncol. 25, 2902–2908 (2007). One of the first detailed reviews of this new treatment.
Nagy, J. A., Meyers, M. S., Masse, E. M., Herzberg, K. T. & Dvorak, H. F. Pathogenesis of ascites tumor growth: fibrinogen influx and fibrin accumulation in tissues lining the peritoneal cavity. Cancer Res. 55, 369–375 (1995).
Yoshiji, H. et al. The vascular endothelial growth factor receptor KDR/Flk-1 is a major regulator of malignant ascites formation in the mouse hepatocellular carcinoma model. Hepatology 33, 841–847 (2001).
Spannuth, W. A., Sood, A. K. & Coleman, R. L. Angiogenesis as a strategic target for ovarian cancer therapy. Nature Clin. Pract. Oncol. 5, 194–204 (2008). An excellent recent review of this topic.
Mesiano, S., Ferrara, N. & Jaffe, R. B. Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization. Am. J. Pathol. 153, 1249–1256 (1998).
Gossmann, A. et al. Magnetic resonance imaging in an experimental model of human ovarian cancer demonstrating altered microvascular permeability after inhibition of vascular endothelial growth factor. Am. J. Obstet. Gynecol. 183, 956–963 (2000).
Hu, L. et al. Vascular endothelial growth factor immunoneutralization plus paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer. Am. J. Pathol. 161, 1917–1924 (2002).
Byrne, A. T. et al. Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model. Clin. Cancer Res. 9, 5721–5728 (2003).
Xu, L. et al. Inhibition of malignant ascites and growth of human ovarian carcinoma by oral administration of a potent inhibitor of the vascular endothelial growth factor receptor tyrosine kinases. Int. J. Oncol. 16, 445–454 (2000).
Machida, S. et al. Inhibition of peritoneal dissemination of ovarian cancer by tyrosine kinase receptor inhibitor SU6668 (TSU-68). Int. J. Cancer 114, 224–229 (2005).
Cannistra, S. A. et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J. Clin. Oncol. 25, 5180–5186 (2007).
Burger, R. A., Sill, M. W., Monk, B. J., Greer, B. E. & Sorosky, J. I. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J. Clin. Oncol. 25, 5165–5171 (2007).
Han, E. S. & Monk, B. J. What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer? Gynecol. Oncol. 105, 3–6 (2007).
Kaye, S. B. Bevacizumab for the treatment of epithelial ovarian cancer: will this be its finest hour? J. Clin. Oncol. 25, 5150–5152 (2007).
Tew, W. P. et al. VEGF-Trap for patients with recurrent platinum-resistant epithelial ovarian cancer (EOC): preliminary results of a randomized, multicenter phase II study. J. Clin. Oncol. 25 (Suppl.), 5508 (2007).
Biagi, J. J. et al. A phase II study of sunitinib (SU11248) in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma - NCIC GTG IND 185. J. Clin. Oncol. 26, (Suppl.), 5522 (2008).
Friedlander, M. et al. Pazopanib (GW786034) is active in women with advanced epithelial ovarian, fallopian tube and peritoneal cancers: initial results of a phase II study. J. Clin. Oncol. 25 (Suppl.), 5561 (2007).
Hirte, H. W. et al. A phase II study of cediranib (AZD2171) in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: Final results of a PMH, Chicago and California consortia trial. J. Clin. Oncol. 26 (Suppl.), 5521 (2008).
Matei, D., Sill, M. W., De Geest, K. & Bristow, R. E. Phase II trial of sorafenib in persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC): a Gynecologic Oncology Group (GOG) study. J. Clin. Oncol. 26 (Suppl.), 5537 (2008).
Matulonis, U. A. et al. Cediranib (AZD2171) is an active agent in recurrent epithelial ovarian cancer. J. Clin. Oncol. 26 (Suppl.), 5501 (2008).
Fukumura, D. & Jain, R. K. Tumor microenvironment abnormalities: causes, consequences, and strategies to normalize. J. Cell. Biochem. 101, 937–949 (2007).
Hu, L. et al. Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model. Clin. Cancer Res. 11, 6966–6971 (2005).
Garofalo, A. et al. The combination of the tyrosine kinase receptor inhibitor SU6668 with paclitaxel affects ascites formation and tumor spread in ovarian carcinoma xenografts growing orthotopically. Clin. Cancer Res. 9, 3476–3485 (2003).
Naumova, E. et al. The vascular targeting property of paclitaxel is enhanced by SU6668, a receptor tyrosine kinase inhibitor, causing apoptosis of endothelial cells and inhibition of angiogenesis. Clin. Cancer Res. 12, 1839–1849 (2006).
Zhong, X. et al. Mechanisms underlying the synergistic effect of SU5416 and cisplatin on cytotoxicity in human ovarian tumor cells. Int. J. Oncol. 25, 445–451 (2004).
Azad, N. S. et al. Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J. Clin. Oncol. 26, 3709–3714 (2008). One of the first studies describing the challenges associated with combinations of targeted treatments.
Nimeiri, H. S. et al. Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia. Gynecol. Oncol. 110, 49–55 (2008).
Nathan, P. et al. A phase I study of combretastatin A4 phosphate (CA4P) and bevacizumab in subjects with advanced solid tumors. J. Clin. Oncol. 26 (Suppl.), 3550 (2008).
Shaked, Y. et al. Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science 313, 1785–1787 (2006).
Schilder, R. J. et al. Phase II evaluation of imatinib mesylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group Study. J. Clin. Oncol. 26, 3418–3425 (2008).
Henriksen, R. et al. Expression and prognostic significance of platelet-derived growth factor and its receptors in epithelial ovarian neoplasms. Cancer Res. 53, 4550–4554 (1993).
Matei, D. et al. Autocrine activation of PDGFRα promotes the progression of ovarian cancer. Oncogene 25, 2060–2069 (2006).
Alberts, D. S. et al. Phase II trial of imatinib mesylate in recurrent, biomarker positive, ovarian cancer (Southwest Oncology Group Protocol S0211). Int. J. Gynecol. Cancer 17, 784–788 (2007).
Coleman, R. L. et al. Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers. Gynecol. Oncol. 101, 126–131 (2006).
Matei, D. et al. Imatinib mesylate in combination with docetaxel for the treatment of patients with advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis: a Hoosier Oncology Group trial. Cancer 113, 723–732 (2008).
Posadas, E. M. et al. A prospective analysis of imatinib-induced c-KIT modulation in ovarian cancer: a phase II clinical study with proteomic profiling. Cancer 110, 309–317 (2007).
Matei, D., Chang, D. D. & Jeng, M. H. Imatinib mesylate (Gleevec) inhibits ovarian cancer cell growth through a mechanism dependent on platelet-derived growth factor receptor α and Akt inactivation. Clin. Cancer Res. 10, 681–690 (2004).
Jayson, G. C. et al. Blockade of platelet-derived growth factor receptor-β by CDP860, a humanized, PEGylated di-Fab', leads to fluid accumulation and is associated with increased tumor vascularized volume. J. Clin. Oncol. 23, 973–981 (2005).
Bergers, G., Song, S., Meyer-Morse, N., Bergsland, E. & Hanahan, D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J. Clin. Invest. 111, 1287–1295 (2003).
Bartlett, J. M. et al. The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer. Br. J. Cancer 73, 301–306 (1996).
Fischer-Colbrie, J. et al. EGFR and steroid receptors in ovarian carcinoma: comparison with prognostic parameters and outcome of patients. Anticancer Res. 17, 613–619 (1997).
Sirotnak, F. M. Studies with ZD1839 in preclinical models. Semin. Oncol. 30, 12–20 (2003).
Sirotnak, F. M., Zakowski, M. F., Miller, V. A., Scher, H. I. & Kris, M. G. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin. Cancer Res. 6, 4885–4892 (2000).
Ciardiello, F. et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin. Cancer Res. 6, 2053–2063 (2000).
Schilder, R. J. et al. Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study. Clin. Cancer Res. 11, 5539–5548 (2005).
Bookman, M. A., Darcy, K. M., Clarke-Pearson, D., Boothby, R. A. & Horowitz, I. R. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J. Clin. Oncol. 21, 283–290 (2003).
Kaye, S. B. et al. A randomised phase II study evaluating the combination of carboplatin-based chemotherapy wiht pertuzumab versus carboplatin-based therapy alone in patients with relapsed, platinum sensitive ovarian cancer. J. Clin. Oncol. 26 (Suppl.), 5520 (2008).
Amler, L. et al. HER pathway gene expression analysis in a phase II study of pertuzumab + gemcitabine vs gemcitabine + placebo in patients with platinum-resistant epithelial ovarian cancer. J. Clin. Oncol. 26 (Suppl.), 5552 (2008).
Elnakat, H. & Ratnam, M. Role of folate receptor genes in reproduction and related cancers. Front. Biosci. 11, 506–519 (2006).
Kalli, K. R. et al. Folate receptor α as a tumor target in epithelial ovarian cancer. Gynecol. Oncol. 108, 619–626 (2008).
Ebel, W. et al. Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-α. Cancer Immun. 7, 6 (2007).
Armstrong, D. et al. Exploratory phase II efficacy study of MORAb-003, a monoclonal antibody against folate receptor-α, in platinum-sensitive ovarian cancer in first relapse. J. Clin. Oncol. 26 (Suppl.), 5500 (2008).
Gibbs, D. D. et al. BGC 945, a novel tumor-selective thymidylate synthase inhibitor targeted to α-folate receptor-overexpressing tumors. Cancer Res. 65, 11721–11728 (2005).
Ame, J. C., Spenlehauer, C. & de Murcia, G. The PARP superfamily. Bioessays 26, 882–893 (2004).
Dantzer, F. et al. Base excision repair is impaired in mammalian cells lacking poly(ADP-ribose) polymerase-1. Biochemistry 39, 7559–7569 (2000).
Tutt, A. N. et al. Exploiting the DNA repair defect in BRCA mutant cells in the design of new therapeutic strategies for cancer. Cold Spring Harb. Symp. Quant. Biol. 70, 139–148 (2005).
Gudmundsdottir, K. & Ashworth, A. The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability. Oncogene 25, 5864–5874 (2006).
Ashworth, A. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J. Clin. Oncol. 26, 3785–3790 (2008). An excellent recent review of PARP inhibitors.
Farmer, H. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917–921 (2005).
Bryant, H. E. et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434, 913–917 (2005). References 79 and 80 describe the basis of this new approach for the first time.
Fong, P. C. et al. Phase I pharmacokinetic (PK) and pharmacodynamic (PD) evaluation of a small molecule inhibitor of poly ADP-ribose polymerase (PARP), KU-0059436 (Ku) in patients (p) with advanced tumours. J. Clin. Oncol. 24 (Suppl.), 3022 (2006).
Yap, T. A. et al. First in human phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of KU-0059436 (Ku), a small molecule inhibitor of poly ADP-ribose polymerase (PARP) in cancer patients (p), including BRCA1/2 mutation carriers. J. Clin. Oncol. 25 (Suppl.), 3529 (2007).
Fong, P. C. et al. AZD2281 (KU-0059436), a PARP (poly ADP-ribose polymerase) inhibitor with single agent anticancer activity in patients with BRCA deficient ovarian cancer: results from a phase I study. J. Clin. Oncol. 26 (Suppl.), 5510 (2008).
Carden, C. et al. A Phase I study of AZD2281 (KU-0059436), a PARP (poly ADP-ribose polymerase) inhibitor: results in patients with BRCA deficient ovarian cancer (BDOC). Abst. BOA22, 320. (National Cancer Research Institute Cancer Conference, 2008].
Turner, N., Tutt, A. & Ashworth, A. Hallmarks of 'BRCAness' in sporadic cancers. Nature Rev. Cancer 4, 814–819 (2004).
McCabe, N. et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res. 66, 8109–8115 (2006).
Press, J. Z. et al. Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer 8, 17 (2008).
Engelman, J. A., Luo, J. & Cantley, L. C. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nature Rev. Genet. 7, 606–619 (2006).
Hu, L., Hofmann, J. & Jaffe, R. B. Phosphatidylinositol 3-kinase mediates angiogenesis and vascular permeability associated with ovarian carcinoma. Clin. Cancer Res. 11, 8208–8212 (2005).
Vivanco, I. & Sawyers, C. L. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nature Rev. Cancer 2, 489–501 (2002).
Yap, T. A. et al. Targeting the PI3K–AKT–mTOR pathway: progress, pitfalls, and promises. Curr. Opin. Pharmacol. 8, 393–412 (2008).
Hennessy, B. T., Smith, D. L., Ram, P. T., Lu, Y. & Mills, G. B. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nature Rev. Drug Discov. 4, 988–1004 (2005). An excellent review of this important topic.
Lopiccolo, J., Blumenthal, G. M., Bernstein, W. B. & Dennis, P. A. Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist. Updat. 11, 32–50 (2008).
Shayesteh, L. et al. PIK3CA is implicated as an oncogene in ovarian cancer. Nature Genet. 21, 99–102 (1999).
Levine, D. A. et al. Frequent mutation of the PIK3CA gene in ovarian and breast cancers. Clin. Cancer Res. 11, 2875–2878 (2005).
Campbell, I. G. et al. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res. 64, 7678–7681 (2004).
Philp, A. J. et al. The phosphatidylinositol 3′-kinase p85α gene is an oncogene in human ovarian and colon tumors. Cancer Res. 61, 7426–7429 (2001).
Trotman, L. C. & Pandolfi, P. P. PTEN and p53: who will get the upper hand? Cancer Cell 3, 97–99 (2003).
Obata, K. et al. Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors. Cancer Res. 58, 2095–2097 (1998).
Jiang, B. H. & Liu, L. Z. PI3K/PTEN signaling in tumorigenesis and angiogenesis. Biochim. Biophys. Acta 1784, 150–158 (2008).
Cheng, J. Q., Lindsley, C. W., Cheng, G. Z., Yang, H. & Nicosia, S. V. The Akt/PKB pathway: molecular target for cancer drug discovery. Oncogene 24, 7482–7492 (2005).
Page, C. et al. Overexpression of Akt/AKT can modulate chemotherapy-induced apoptosis. Anticancer Res. 20, 407–416 (2000).
Hu, L., Hofmann, J., Lu, Y., Mills, G. B. & Jaffe, R. B. Inhibition of phosphatidylinositol 3′-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res. 62, 1087–1092 (2002).
Yang, X., Fraser, M., Moll, U. M., Basak, A. & Tsang, B. K. Akt-mediated cisplatin resistance in ovarian cancer: modulation of p53 action on caspase-dependent mitochondrial death pathway. Cancer Res. 66, 3126–3136 (2006).
Arboleda, M. J. et al. Overexpression of AKT2/protein kinase Bβ leads to up-regulation of β1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells. Cancer Res. 63, 196–206 (2003).
Yuan, Z. Q. et al. Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer. Oncogene 19, 2324–2330 (2000).
Cheng, J. Q. et al. AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. Proc. Natl Acad. Sci. USA 89, 9267–9271 (1992).
Bellacosa, A. et al. Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int. J. Cancer 64, 280–285 (1995).
Nakayama, K. et al. Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms. Cancer Biol. Ther. 5, 779–785 (2006).
Carpten, J. D. et al. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 448, 439–444 (2007).
Oza, A. et al. A phase II study of temsirolimus (CCI-779) in patients with metastatic and/or locally advanced recurrent endometrial cancer previously treated with chemotherapy: NCIC CTG IND 160b. J. Clin. Oncol. 26 (Suppl.), 5516 (2008).
Slomovitz, B. et al. A phase II study of oral mammalian target of rapamycin (mTOR) inhibitor, RAD001 (everolimus), in patients with recurrent endometrial carcinoma (EC). J. Clin. Oncol. 26 (Suppl.), 5502 (2008).
Wiener, J. R. et al. Activated SRC protein tyrosine kinase is overexpressed in late-stage human ovarian cancers. Gynecol. Oncol. 88, 73–79 (2003).
Dressman, H. K. et al. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. J. Clin. Oncol. 25, 517–525 (2007). An important paper that highlights the role of the oncogene SRC in ovarian cancer.
Yu, K., Toral-Barza, L., Shi, C., Zhang, W. G. & Zask, A. Response and determinants of cancer cell susceptibility to PI3K inhibitors: combined targeting of PI3K and Mek1 as an effective anticancer strategy. Cancer Biol. Ther. 7, 307–315 (2008).
Tan, D.S. et al. PPM1D is a potential therapeutic target in ovarian clear cell carcinomas. Clin. Cancer Res. (in the press).
Visvader, J. E. & Lindeman, G. J. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nature Rev. Cancer 8, 755–768 (2008).
Szotek, P. P. et al. Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian inhibiting substance responsiveness. Proc. Natl Acad. Sci. USA 103, 11154–11159 (2006). An important paper confirming the existence of cancer stem cells in ovarian cancer.
Zhang, S. et al. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res. 68, 4311–4320 (2008).
Workman, P. & Kaye, S. B. Translating basic cancer research into new cancer therapeutics. Trends Mol. Med. 8, S1–S9 (2002).
Futreal, P. A. et al. Cancer and genomics. Nature 409, 850–852 (2001).
Lander, E. S. et al. Initial sequencing and analysis of the human genome. Nature 409, 860–921 (2001).
Venter, J. C. et al. The sequence of the human genome. Science 291, 1304–1351 (2001).
Thomas, G. V. mTOR and cancer: reason for dancing at the crossroads? Curr. Opin. Genet. Dev. 16, 78–84 (2006).
Banerji, U., de Bono, J., Judson, I., Kaye, S. & Workman, P. Biomarkers in early clinical trials: the committed and the skeptics. Clin. Cancer Res. 14, 2512 (2008).
Workman, P. Auditing the pharmacological accounts for Hsp90 molecular chaperone inhibitors: unfolding the relationship between pharmacokinetics and pharmacodynamics. Mol. Cancer Ther. 2, 131–138 (2003).
Workman, P. How much gets there and what does it do? The need for better pharmacokinetic and pharmacodynamic endpoints in contemporary drug discovery and development. Curr. Pharm. Des. 9, 891–902 (2003).
Sarker, D. & Workman, P. Pharmacodynamic biomarkers for molecular cancer therapeutics. Adv. Cancer Res. 96, 213–268 (2007).
Srinivasan, M., Sedmak, D. & Jewell, S. Effect of fixatives and tissue processing on the content and integrity of nucleic acids. Am. J. Pathol. 161, 1961–1971 (2002).
Wu, J. M. et al. Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases. Clin. Cancer Res. 14, 1938–1946 (2008).
Chan, J. K. et al. A novel technique for the enrichment of primary ovarian cancer cells. Am. J. Obstet. Gynecol. 197, 507 e1–e5 (2007).
Barker, S. D. et al. An immunomagnetic-based method for the purification of ovarian cancer cells from patient-derived ascites. Gynecol. Oncol. 82, 57–63 (2001).
Provencher, D. M. et al. Comparison of antigen expression on fresh and cultured ascites cells and on solid tumors of patients with epithelial ovarian cancer. Gynecol. Oncol. 50, 78–83 (1993).
Puiffe, M. L. et al. Characterization of ovarian cancer ascites on cell invasion, proliferation, spheroid formation, and gene expression in an in vitro model of epithelial ovarian cancer. Neoplasia 9, 820–829 (2007).
Forster, M. D., Ormerod, M. G., Agarwal, R., Kaye, S. B. & Jackman, A. L. Flow cytometric method for determining folate receptor expression on ovarian carcinoma cells. Cytometry A 71, 945–950 (2007).
Pantel, K., Brakenhoff, R. H. & Brandt, B. Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nature Rev. Cancer 8, 329–340 (2008).
Marth, C., Kisic, J., Kaern, J., Trope, C. & Fodstad, O. Circulating tumor cells in the peripheral blood and bone marrow of patients with ovarian carcinoma do not predict prognosis. Cancer 94, 707–712 (2002).
Nagrath, S. et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 450, 1235–1239 (2007).
Sessa, C. et al. Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails. J. Clin. Oncol. 23, 1867–1874 (2005).
Krasner, C. N. et al. A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens. Br. J. Cancer 97, 1618–1624 (2007).
del Campo, J. et al. Phase II open label randomized study of trabectedin (T) given as two different dosing schedules in women with platinum-sensitive, recurrent ovarian carcinoma: preliminary results. J. Clin. Oncol. 24 (Suppl.), 5031 (2006).
Smit, W. M. et al. Phase I/II dose-escalation trial of patupilone every 3 weeks in patients with relapsed/refractory ovarian cancer. J. Clin. Oncol. 23 (Suppl.), 5056 (2005).
Forster, M. et al. A phase Ib and pharmacokinetic trial of patupilone combined with carboplatin in patients with advanced cancer. Clin. Cancer Res. 13, 4178–4184 (2007).
Kavanagh, J. J. et al. Multi-institutional phase 2 study of TLK286 (TELCYTA, a glutathione S-transferase P1–1 activated glutathione analog prodrug) in patients with platinum and paclitaxel refractory or resistant ovarian cancer. Int. J. Gynecol. Cancer 15, 593–600 (2005).
Rose, P. et al. Canfosfamide (C, TLK286) plus carboplatin (P) vs. liposomal doxorubicin (D) as 2nd line therapy of platinum (P) resistant ovarian cancer (OC): phase 3 study results. J. Clin. Oncol. 25 (Suppl.), 5529 (2007).
Vergote, I. et al. Single agent, canfosfamide (C, TLK286) vs pegylated liposomal doxorubicin (D) or topotecan (T) in 3rd line treatment of platinum (P) refractory or resistant ovarian cancer (OC): phase 3 study results. J. Clin. Oncol. 25 (Suppl.), 5528 (2007).
Garcia, A. A. et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J. Clin. Oncol. 26, 76–82 (2008).
McGonigle, K. F. et al. A phase II prospective study of weekly topotecan and bevacizumab in platinum refractory ovarian or peritoneal cancer. J. Clin. Oncol. 26 (Suppl.), 5551 (2008).
Micha, J. P. et al. A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancer. Int. J. Gynecol. Cancer 17, 771–776 (2007).
Campos, S. M. et al. Safety of maintenance bevacizumab after first-line chemotherapy for advanced ovarian and mullerian cancers. J. Clin. Oncol. 25 (Suppl.), 5517 (2007).
Posadas, E. M. et al. A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer. Cancer 109, 1323–1330 (2007).
Slomovitz, B. M. et al. Phase I study of weekly topotecan and gefitinib in patients with platinum-resistant ovarian, peritoneal, or fallopian tube cancer. J. Clin. Oncol. 24 (Suppl.), 5090 (2006).
Pautier, F. et al. Gefitinib in combination with paclitaxel and carboplatin as second-line therapy for ovarian, tubal or peritoneal adenocarcinoma: final results of a phase II study. J. Clin. Oncol. 25 (Suppl.), 5566 (2007).
Wagner, U. et al. Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum-taxane based therapy — a phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6). Gynecol. Oncol. 105, 132–137 (2007).
Gordon, A. N. et al. Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study. Int. J. Gynecol. Cancer 15, 785–792 (2005).
Vasey, P. A. et al. A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers. Br. J. Cancer 98, 1774–1780 (2008).
Blank, S. V. et al. Report of first-stage accrual for NCI 5886, a phase II study of erlotinib, carboplatin and paclitaxel as first-line treatment of ovarian cancer. J. Clin. Oncol. 24 (Suppl.), 5076 (2006).
Schilder, R. J. et al. Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash. Gynecol. Oncol. 21 Jan 2009 (doi:10.1016/j.ygyno.2008.12.003).
Konner, J. et al. A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer. Gynecol. Oncol. 110, 140–145 (2008).
Secord, A. A. et al. Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: a Gynecologic Oncology Group study. Gynecol. Oncol. 108, 493–499 (2008).
Seiden, M. V. et al. A phase II trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody, in patients with platinum-resistant ovarian and primary peritoneal malignancies. Gynecol. Oncol. 104, 727–731 (2007).
Gordon, M. S. et al. Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. J. Clin. Oncol. 24, 4324–4332 (2006).
Rivkin, S. E. et al. Phase I/II lapatinib plus carboplatin and paclitaxel in stage III or IV relapsed ovarian cancer patients. J. Clin. Oncol. 26 (Suppl.), 5556 (2008).
Campos, S. et al. Multicenter, randomized phase II trial of oral CI-1033 for previously treated advanced ovarian cancer. J. Clin. Oncol. 23, 5597–5604 (2005).
Armstrong, D. K. et al. Exploratory phase II efficacy study of MORAb-003, a monoclonal antibody against folate receptor-α, in platinum-sensitive ovarian cancer in first relapse. J. Clin. Oncol. 26, 1 (2008).
Acknowledgements
The Drug Development Unit is supported by Cancer Research UK through a programme grant to the Section of Medicine, Institute of Cancer Research, and through an Experimental Cancer Medical Centre (ECMC) grant (C51/A7401). It is also supported by the Department of Health through the ECMC grant and as part of the National Institutes of Health Research Biomedical Research Centre at the Royal Marsden Hospital. T.A.Y., C.P.C. and S.B.K. are employees of The Institute of Cancer Research. T.A.Y. and C.P.C. are Cancer Research UK Clinical Research Fellows (C309/A8274 and C1178/A7851). We would like to thank L. Readings for her invaluable assistance with the preparation of the manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
Stan B. Kaye serves on advisory boards for the following companies: AstraZeneca, Genentech, OSI Pharmaceuticals Inc. and PharmaMar. Timothy A. Yap and Craig P. Carden do not have any competing interests.
Supplementary information
Supplementary information S1 (table)
Novel targets in ovarian cancer (PDF 350 kb)
Related links
Related links
DATABASES
ClinicalTrials.gov
National Cancer Institute Drug Dictionary
FURTHER INFORMATION
Glossary
- FIGO stages
-
(The International Federation of Gynecology and Obstetrics stages). This system describes a classification of the stage of ovarian cancer as determined by surgical and pathological findings.
- Platinum-sensitive disease
-
Recurrence of disease on platinum chemotherapy after more than 6 months.
- Platinum-resistant disease
-
Recurrence of disease on platinum chemotherapy after less than 6 months.
- Platinum-refractory disease
-
Recurrence of disease during or on completion of platinum chemotherapy.
- CTCAE
-
(Common Terminology Criteria for Adverse Events).
This is a descriptive terminology which can be used for adverse event reporting. A grading scale is provided for each adverse event term and the grade refers to the severity of the adverse event.
- Hand–foot syndrome
-
A condition marked by pain, swelling, numbness, tingling or redness of the hands or feet. It sometimes occurs as a side effect of certain anticancer drugs. It is also called palmar–plantar erythrodysaesthesia.
- Fistula
-
An abnormal opening or passage between two organs or between an organ and the surface of the body.
- Cancer antigen 125
-
(CA125). A tumour biomarker that is clinically approved for monitoring the response to anticancer treatment and predicting prognosis following treatment in ovarian cancer and other malignancies.
- Synthetic lethality
-
A lethal synergy between two otherwise non-lethal events.
- IC50
-
The half maximal inhibitory concentration is the concentration of a drug that is required for 50% inhibition in vitro and is commonly used as a measure of drug potency in pharmacological research.
- BRCAness
-
A term that describes the traits that some sporadic cancers share with those that occur in carriers with mutations in BRCA1 or BRCA2. This sharing of characteristics might have important implications for the clinical management of these cancers.
- Pharmacological audit trail
-
This describes a framework that systematically traces all phases of drug development, from target identification to clinical outcome and permits rational 'go' or 'no-go' decisions to be made in a hypothesis-testing manner, guiding the successful development of modern therapeutics.
Rights and permissions
About this article
Cite this article
Yap, T., Carden, C. & Kaye, S. Beyond chemotherapy: targeted therapies in ovarian cancer. Nat Rev Cancer 9, 167–181 (2009). https://doi.org/10.1038/nrc2583
Issue Date:
DOI: https://doi.org/10.1038/nrc2583
This article is cited by
-
Cytoreductive surgery is feasible in patients with limited regional platinum-resistant recurrent ovarian cancer
World Journal of Surgical Oncology (2023)
-
TWIST1 induces proteasomal degradation of β-catenin during the differentiation of ovarian cancer stem-like cells
Scientific Reports (2022)
-
Selective mediation of ovarian cancer SKOV3 cells death by pristine carbon quantum dots/Cu2O composite through targeting matrix metalloproteinases, angiogenic cytokines and cytoskeleton
Journal of Nanobiotechnology (2021)
-
Chemotherapy confers a conserved secondary tolerance to EGFR inhibition via AXL-mediated signaling bypass
Scientific Reports (2021)
-
Chemotherapy is not necessary for early-stage serous and endometrioid ovarian cancer after undergoing comprehensive staging surgery
Journal of Ovarian Research (2020)